IDEXX Laboratories Announces Promotion of Dupree and Williams to Corporate Vice President

Westbrook, Maine, November 1, 2006—IDEXX Laboratories, Inc. (NASDAQ: IDXX), announced today the appointments of Thomas J. Dupree and Michael Williams, PhD, to the position of Corporate Vice President.

Thomas J. ("TJ") Dupree assumes the role of Corporate Vice President in recognition of his track record of strategic and operational leadership at IDEXX. He joined IDEXX in March 2003 as Vice President for Business Development and, according to Chairman and CEO Jonathan Ayers, “has been instrumental in the purchase and integration of several strategic business acquisitions and alliances at IDEXX Laboratories, notably the addition of Germany-based Vet Med Labor and the purchase of Switzerland-based Dr. Bommeli AG.”

As leader of the Company's Rapid Assay team, Mr. Dupree spearheaded the acceleration and growth of existing products and oversaw the successful launch of SNAP® 4Dx®, a revolutionary test that screens for three tick-borne diseases, Ehrlichia canis, Lyme disease and Anaplasma phagocytophilum as well as heartworm in dogs.

Mr. Dupree holds an undergraduate degree from Colby College, where he double-majored in Economics and German, and an MBA from the University of Virginia. After receiving his MBA, he worked for seven years at the Boston Consulting Group (BCG), a business strategy consulting firm. Prior to joining IDEXX in 2003, Mr. Dupree spent four years with Bath Iron Works in various management and supervisory capacities.

Michael Williams, PhD, has been named Corporate Vice President in recognition of his leadership and business growth achievements in the IDEXX VetLab® instrument line of business.

Since joining IDEXX in 2003, says Ayers, “Michael has revitalized the growth of the Company's IDEXX VetLab instrument and reagent business through new product introductions and a focus on new customer acquisition. He provided critical insight and leadership in significantly expanding the Company's direct sales organization and ensuring a steady stream of innovations that have added significant value to IDEXX Laboratories' VetLab® Suite of instruments.” Dr. Williams has also developed the Company's leadership team through field sales promotions and new hires, as well as the recruitment of several executives.

Dr. Williams holds a PhD in Biochemistry from the University of Oxford. Prior to joining IDEXX, he worked as a Senior Research Associate at the Scripps Research Institute for several years and then joined McKinsey & Company for seven years as a healthcare strategy consultant.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 (1.5 MB) and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, (520 KB) in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”